Fennec Pharmaceuticals Inc. Common Stock (NASDAQ: FENC)
According to the Complaint, Fennec Pharmaceuticals Inc. is a biopharmaceutical company that purportedly focuses on the development of PEDMARK, a sodium thiosulfate anhydrous injection, for the prevention of platinum-induced ototoxicity in pediatric cancer patients.